MedTrace Logo

Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT01072383 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2012-03-13

No results posted yet for this study

Summary

This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

BT061

administration of BT061 either intravenous or subcutaneous

DRUG

placebo treatment

administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous

Sponsors & Collaborators

  • Biotest

    lead INDUSTRY

Principal Investigators

  • Lajos Kemény, M.D. · Szegedi Tudományegyetem (Study site)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-06-30
Completion
2011-08-31

Countries

  • Czechia
  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01072383 on ClinicalTrials.gov